REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?
Replimune Group Inc. shares (REPL) fell about 19% after the FDA refused approval for its melanoma drug RP1. The FDA said the resubmitted data were insufficient to show substantial evidence of effectiveness for unresectable advanced cutaneous melanoma, and noted different reviewers for objectivity. The company can resubmit or withdraw within a year.
How this was made
The 30-second read
Why it matters
A refusal based on insufficient evidence of effectiveness resets the approval timeline and increases uncertainty around the next regulatory path (resubmit vs withdraw).
Market read
This is a direct FDA regulatory denial for a specific oncology asset, which is typically a high-impact catalyst for biotech valuation and trading positioning.
What to watch
The FDA also cited reviewer-team changes for objectivity, which may imply the resubmission process and evidence package quality are the key gating items, not the underlying biology alone.
Background
FDA previously issued a complete response letter for RP1 in combination with nivolumab in late July 2025, and Replimune resubmitted in October with additional analyses but no new trial.
Ticker impact
FDA refused approval for Replimune’s melanoma drug RP1, saying submitted data is insufficient for substantial evidence of effectiveness.
Bearish bias for the next several sessions as traders reprice the approval timeline and resubmission odds.
The article cites a direct FDA refusal letter and notes no new trial was added in the resubmission, which typically lowers odds of near-term approval.
Market effects
Highlights heightened FDA scrutiny for oncology efficacy evidence, potentially weighing on similar-stage biotech sentiment.
Primarily US biotech sentiment impact via FDA decision channel.
US regulatory outcome can affect global investor risk appetite for melanoma and immuno-oncology programs.
Counterpoint
The company still has a one-year window to resubmit, so the denial may be a setback rather than a terminal outcome if new evidence is generated.
Key entities
- companyReplimune Group Inc.
Subject of the FDA refusal for its melanoma drug RP1.
- regulatorU.S. Food and Drug Administration (FDA)
Issued the refusal letter citing insufficient evidence of effectiveness and maintained the prior conclusion.
- drugRP1
Experimental melanoma drug whose approval was refused.
- drugNivolumab
Referenced as part of the earlier RP1 combination application.
